HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EWG To FDA Commish: Sunscreen SPFs Require ‘Urgent’ Investigation

This article was originally published in The Rose Sheet

Executive Summary

The Environmental Working Group renews its call for a cap on SPF values at 50+, asking FDA to investigate whether anti-inflammatory ingredients added to sunscreen formulations are boosting SPFs without providing meaningful protection against UV damage. The NGO also recommends changes to the agency’s SPF testing requirements to improve the accuracy of labeled SPF claims.

You may also be interested in...



PCPC Continues Efforts To Set Record Straight On Sunscreens

Recent “alarmist reports” and studies regarding the state of the US sunscreen market and the merits of UV-protective products available to consumers are sending a potentially confusing message, which could discourage sunscreen use at a time of epidemic skin-cancer rates, the Personal Care Products Council suggests. The group hosted a webinar July 11 to clarify sunscreen regulations and promote daily use.

EWG's Claims About US Sunscreen Market, Skin-Cancer Prevention Analyzed

"The Rose Sheet" examines the Environmental Working Group's assertion that half of the US sunscreens it evaluated for its 2016 report and shopping guide likely would not be marketable in Europe due to inadequate UVA protection. The NGO's suggestion that sunscreen's capacity for preventing skin cancer has not been demonstrated also invites scrutiny.

Califf's Priorities Feature Short- And Long-Term Goals Despite Potentially Brief Tenure

Newly confirmed FDA Commissioner Robert Califf should not assume he will be leaving once a new president arrives, a Republican-appointed predecessor says.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108512

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel